Malaysia Warns E-Cigarette Treatment Costs Could Hit $80M by 2030

Nov.14.2024

Malaysia's Health Ministry warns that treatment costs for e-cigarette-related lung injuries (Evali) could surge to $82.24 million by 2030, while 41 Evali cases have been reported since 2019.

According to Free Malaysia Today's report on November 14th, the Malaysian Ministry of Health (KKM) has warned that the treatment costs for the illness related to the use of e-cigarettes or vaping products, known as "Evali," are expected to soar to 369 million Malaysian Ringgit (82.24 million USD) by 2030.

The Minister of Health, Dzulkefly Ahmad, stated that as of now, the government has borne approximately 150,892.11 Malaysian Ringgit (30,000 USD) in treatment costs for each patient hospitalized for 12 days due to Evali.

From 2019 to September 30, 2024, the Ministry of Health has reported a total of 41 cases of Evali. In addition, the National Poison Center has received a total of 111 accident notifications caused by e-cigarettes or e-cigarette liquids from 2015 to 2023.

The minister stated that the Public Health Tobacco Control Act 2024 will come into effect on October 1st, with the aim of curbing the use of e-cigarettes, especially among children and adolescents. The law not only aims to protect young people from the influence of e-cigarettes, but also seeks to reduce the government's future healthcare costs burden. The law imposes strict restrictions on the advertising, promotion, sponsorship, and sale of e-cigarette products to minors.

References:

[1] KKM tanggung RM150,000 rawat 1 pesakit Evali, kata Dzulkefly

Also Read:

[1] Malaysia approves 147 vape firms under new tobacco control law

[2] Malaysian PM reports more than $40 million in e-cigarette taxes collected in 3 years, revenue to fund government projects

[3] Malaysian Authorities Urged to Crack Down on E-Cigarette Sales

[4] Malaysia's Health Minister: No Need to Follow Foreign E-Cig Bans, Focus on Enforcing New Smoking Control Act

[5] Strengthening Enforcement of Smoke-Free Zones in Malaysia: Ministry of Health.

#Asia #Open system e-cigarettes #Regulation #Malaysia

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months

The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.

Oct.20 by 2FIRSTS.ai

U.S. Lawmakers Seek to Empower HHS to Destroy Counterfeit Chinese Tobacco Products

Bipartisan members of the U.S. Congress have introduced the “Ensuring the Necessary Destruction of Illicit Chinese Tobacco Act” (END Act), seeking to amend the Federal Food, Drug, and Cosmetic Act to authorize the Department of Health and Human Services (HHS) to directly destroy adulterated, misbranded, or counterfeit imported tobacco products.Major tobacco companies, including Altria, along with several public health organizations, have announced their support for the bill.

Nov.11 by 2FIRSTS.ai

Belgium Plans to Ban All Vape Flavours Except Tobacco, Backed by Health Council

Belgian Health Minister Frank Vandenbroucke has announced plans to ban all e-cigarette flavours except tobacco, following new advice from the Superior Health Council (CSS). The move marks a major policy shift, as the Council now fully supports flavour restrictions to curb youth vaping.

Nov.19 by 2FIRSTS.ai

Japan Tobacco Expands Ploom Aura EVO Menthol Line With Two New Products and One Upgraded Blend

Japan Tobacco Inc. (JT) has added two new EVO sticks, Evo Black Menthol and Evo Fresh Mint, to its Ploom Aura lineup and reformulated Evo Cold Menthol, creating a menthol range with three distinct levels of cooling intensity and flavor profile.